- Home
- AII vs CAPR Comparison
AII vs CAPR Comparison
Compare AII & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- CAPR
- Stock Information
- Founded
- AII 2006
- CAPR 2005
- Country
- AII United States
- CAPR United States
- Employees
- AII N/A
- CAPR N/A
- Industry
- AII Property-Casualty Insurers
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AII Finance
- CAPR Health Care
- Exchange
- AII Nasdaq
- CAPR Nasdaq
- Market Cap
- AII 370.5M
- CAPR 324.6M
- IPO Year
- AII 2025
- CAPR N/A
- Fundamental
- Price
- AII $19.96
- CAPR $6.28
- Analyst Decision
- AII Buy
- CAPR Strong Buy
- Analyst Count
- AII 4
- CAPR 8
- Target Price
- AII $21.67
- CAPR $24.75
- AVG Volume (30 Days)
- AII 78.8K
- CAPR 1.4M
- Earning Date
- AII 08-12-2025
- CAPR 08-11-2025
- Dividend Yield
- AII N/A
- CAPR N/A
- EPS Growth
- AII N/A
- CAPR N/A
- EPS
- AII 60.71
- CAPR N/A
- Revenue
- AII $260,047,000.00
- CAPR $13,392,150.00
- Revenue This Year
- AII $25.82
- CAPR N/A
- Revenue Next Year
- AII $25.78
- CAPR $6,061.53
- P/E Ratio
- AII $0.33
- CAPR N/A
- Revenue Growth
- AII 1.73
- CAPR N/A
- 52 Week Low
- AII $15.78
- CAPR $3.98
- 52 Week High
- AII $20.32
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- AII N/A
- CAPR 36.33
- Support Level
- AII N/A
- CAPR $6.17
- Resistance Level
- AII N/A
- CAPR $7.30
- Average True Range (ATR)
- AII 0.00
- CAPR 0.43
- MACD
- AII 0.00
- CAPR -0.11
- Stochastic Oscillator
- AII 0.00
- CAPR 4.53
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.